Faculty of 1000 evaluation for A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers.

Filippo Drago, Filippo Caraci
  • August 2013, Faculty of 1000, Ltd.
  • DOI: 10.3410/f.717955710.793481436

The authors haven't yet claimed this publication.

open access logoRead Publication


In partnership with: